Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of ocular allergies within the past 24 months.~* Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.~Exclusion Criteria:~* Any presence of active ocular infection or history of an ocular herpetic infection.~* Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months.~* Have any planned surgery during the study or 30 days after the study.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lastacaft® (Type: ACTIVE_COMPARATOR): One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
- Pataday™ (Type: ACTIVE_COMPARATOR): One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
- Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) (Type: PLACEBO_COMPARATOR): One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).